TITLE

Cardiac Autonomic Neuropathy Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients With Diabetic Nephropathy

AUTHOR(S)
Astrup, Anne Sofie; Tarnow, Lise; Rossing, Peter; Hansen, Birgitte V.; Hilsted, Jannik; Parving, Hans-Henrik
PUB. DATE
February 2006
SOURCE
Diabetes Care;Feb2006, Vol. 29 Issue 2, p334
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE -- Cardiac autonomic neuropathy (CAN) has been associated with a poor prognosis in patients with diabetes. Because CAN is common in patients with diabetic nephropathy, we evaluated the predictive value of CAN in type 1 diabetic patients with and without diabetic nephropathy. RESEARCH DESIGN AND METHODS-- In a prospective observational follow-up study, 197 type 1 diabetic patients with diabetic nephropathy and a matched group of 191 patients with long-standing type 1 diabetes and normoalbuminuria were followed for 10.1 years (range 0.0-10.3 years). At baseline, CAN was assessed by heart rate variation (HRV) during deep breathing. HRV was evaluated as a predictor of the primary end point: cardiovascular morbidity and mortality. As secondary end points, all-cause mortality and the influence of HRV on progression of diabetic nephropathy (decline in glomerular filtration rate [GFR]) was evaluated. RESULTS-- During the follow-up, 79 patients (40%) with nephropathy reached the combined primary end point vs. 19 patients (10%) with normoalbuminuria (log-rank test, P < 0.0001). The unadjusted hazard ratio (HR) for reaching the primary end point when having an abnormal HRV (≤10 bpm) measured at baseline compared with a normal HRV was 7.7 (range 1.9-31.5; P = 0.004) in patients with nephropathy. Similarly in the normoalbuminuric patients, the unadjusted HR was 4.4 (1.4-13.6; P = 0.009). In patients with nephropathy, abnormal HRV was significantly associated with fatal and nonfatal cardiovascular disease after adjustment for cardiovascular risk factors. The adjusted HR for reaching the primary end point in a patient with nephropathy and an abnormal HRV was 6.4 (1.5-26.3, P = 0.010), as compared with a normal HRV. The unadjusted HR for dying when having an abnormal HRV compared with a normal HRV was 3.3 (95% CI 1.0-10.7; P = 0.043) in patients with diabetic nephropathy. After adjustment for confounding factors, the impact of HRV on all-cause mortality in patients with nephropathy was no longer significant (P = 0.293). There was no relationship between abnormal HRV and rate of decline in GFR. CONCLUSIONS-- HRV is an independent risk factor for cardiovascular morbidity and mortality in type 1 diabetic patients with nephropathy.
ACCESSION #
20062956

 

Related Articles

  • Serum Lipids and the Progression of Nephropathy in Type 1 Diabetes. Thomas, Merlin C.; Rosengård-BäRlund, Milla; Mills, Vashti; Rönnback, Mats; Thomas, Stephen; Forsblom, Carol; Cooper, Mark E.; Taskinen, Marja-Riitta; Viberti, Giancarlo; Groop, Per-Henrik // Diabetes Care;Feb2006, Vol. 29 Issue 2, p317 

    OBJECTIVE -- Dyslipidemia contributes to the progression of microvascular disease in diabetes. However, different lipid variables may be important at different stages of nephropatby. This study examines the pattern of dyslipidemia associated with the progression of nephropathy in patients with...

  • Diabetic nephropathy – complications and treatment. Lim, Andy K. H. // International Journal of Nephrology & Renovascular Disease;2014, Vol. 7, p361 

    Diabetic nephropathy is a significant cause of chronic kidney disease and end-stage renal failure globally. Much research has been conducted in both basic science and clinical therapeutics, which has enhanced understanding of the pathophysiology of diabetic nephropathy and expanded the potential...

  • Glycemic control and the initiation and progression of the complications of diabetes mellitus. Steffes, Michael W. // Kidney International Supplement;Dec1997, Issue 63, pS36 

    The effect of improved glycemic control on the prevention or reversal of diabetic nephropathy has been optimally shown by the reduced incidence of albuminuria (accompanied by an increased risk of hypoglycemia) in the Diabetes Control and Complications Trial (DCCT). The earliest detection of the...

  • Nephrology -- Pathophysiology and Pharmacology.  // Current Medical Literature: Nephrology & Hypertension;2006, Vol. 12 Issue 2, p47 

    The article presents the author's reflections in response to articles about the pathophysiology and pharmacology of nephrology. The author discussed recommendations regarding the intake of fluid in patients with chronic kidney disease. The therapeutic potential of angiostatin as well as...

  • Endoplasmic Reticulum and Its Role in Diabetic Nephropathy. Dadras, Farahnaz; Khoshjou, Farhad // Iranian Journal of Kidney Diseases;Jul2015, Vol. 9 Issue 4, p267 

    Endoplasmic reticulum produces folds and exports proteins. There are studies showing the role of endoplasmic reticulum in pathogenesis of diabetic complications including diabetic nephropathy. This article reviews the pathophysiology associated with the role of endoplasmic reticulum in diabetic...

  • Epithelial-to-Mesenchymal Transition in Diabetic Nephropathy: Fact or Fiction? Loeffler, Ivonne; Wolf, Gunter // Cells (2073-4409);2015, Vol. 4 Issue 4, p631 

    The pathophysiology of diabetic nephropathy (DN), one of the most serious complications in diabetic patients and the leading cause of end-stage renal disease worldwide, is complex and not fully elucidated. A typical hallmark of DN is the excessive deposition of extracellular matrix (ECM)...

  • Angiopoietin-2 Is Associated with Albuminuria and Microinflammation in Chronic Kidney Disease. Chang, Fan-Chi; Lai, Tai-Shuan; Chiang, Chih-Kang; Chen, Yung-Ming; Wu, Ming-Shiou; Chu, Tzong-Shinn; Wu, Kwan-Dun; Lin, Shuei-Liong // PLoS ONE;Mar2013, Vol. 8 Issue 3, p1 

    Although cardiovascular disease (CVD) is the leading cause of mortality in patients with chronic kidney disease (CKD), the pathophysiology is not thoroughly understood. Given that elevated albuminuria or circulating angiopoietin-2 associates with CVD and mortality in CKD patients, we were...

  • Citations and Clinicians' Notes: Complications of Diabetes: Nephropathy.  // Current Medical Literature: Diabetes;2003, Vol. 20 Issue 4, p106 

    Presents citations and clinicians' notes on nephropathic complications of diabetes. Progression to overt nephropathy in type 2 diabetes; Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes; Factors predictive of nephropathy in DCCT type 1 diabetic patients with...

  • CITATIONS AND CLINICIANS' NOTES: COMPLICATIONS OF DIABETES -- NEPHROPATHY.  // Current Medical Literature: Diabetes;2004, Vol. 21 Issue 3, p81 

    Cites studies addressing complications of diabetes in relation with nephropathy. Development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes; Percentage rate of patients who developed microalbuminuria and frank proteinuria; Factors influencing the development of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics